Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to NKTX. [ FAQ on what and how to ask] For non-NKTX questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080
Employees: 106
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
CEO & Director
President and Principal Accounting & Financial Officer
Chief Medical Officer and Head of Research & Development
My Watchlist
